Study guide

15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease

Key Takeaways Explain This Topic AI

A STOP-Bang score of 5-8 indicates a high probability of moderate-to-severe obstructive sleep apnoea; such patients are sensitive to opioids and sedatives and should use their CPAP device after surgery.

In obesity, induction doses of propofol are based on lean body weight, suxamethonium on total body weight, rocuronium on ideal body weight (with sugammadex on actual weight), and tidal volume on predicted body weight.

The Child-Pugh score (bilirubin, albumin, INR, ascites and encephalopathy) and the MELD score predict perioperative mortality in cirrhosis; elective surgery in Child-Pugh class C carries very high mortality and is usually avoided.

In chronic kidney disease, avoid suxamethonium if potassium is high, prefer atracurium or cisatracurium, avoid morphine and pethidine (active metabolites accumulate), and protect arteriovenous fistula arms.

In COPD, avoid hyperoxia in patients with chronic hypercapnia, use long expiratory times to limit gas trapping and intrinsic PEEP, and consider regional anaesthesia to reduce postoperative pulmonary complications.

Last updated: October 2026

  • 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease
  • Asthma

Assessment: frequency of symptoms, nocturnal waking, reliever use, previous hospital or intensive care admissions, recent oral steroids and current control. Elective surgery should be deferred if asthma is poorly controlled or after a recent exacerbation (often 4-6 weeks).

Optimisation: continue inhalers including on the day of surgery; give a bronchodilator before induction in symptomatic patients; consider a short course of oral steroids for poorly controlled disease.

Intraoperative management:

Avoid airway instrumentation when possible (supraglottic airway or regional technique).

Propofol and ketamine cause bronchodilation; volatile agents (sevoflurane) are bronchodilators; desflurane is irritant.

Avoid histamine-releasing drugs (morphine, atracurium in large doses) where alternatives exist, and use NSAIDs only in patients known to tolerate them (aspirin-exacerbated respiratory disease affects about 5-10% of adults with asthma).

Ventilate with a low rate, long expiratory time and moderate tidal volume to avoid gas trapping.

Intraoperative bronchospasm: deepen anaesthesia, 100% oxygen, exclude mechanical causes (kinked tube, endobronchial intubation), salbutamol via the circuit, then intravenous salbutamol, magnesium, adrenaline or ketamine; consider anaphylaxis.

Chronic Obstructive Pulmonary Disease (COPD)

Assessment: exercise tolerance, sputum, exacerbations, home oxygen, right heart failure (cor pulmonale), arterial blood gas if severe (baseline P a CO 2 P_a\text{CO}_2 P a ​ CO 2 ​ ), spirometry.

Smoking cessation reduces wound and pulmonary complications; benefits increase with longer abstinence, but stopping at any time helps. Carbon monoxide levels fall within 12-24 hours.

Ventilation: use a low respiratory rate and long expiratory time (I:E 1:3 or longer) to prevent dynamic hyperinflation and intrinsic PEEP , which reduce venous return and can cause hypotension and pneumothorax.

Oxygen: in patients with chronic hypercapnia, target S p O 2 S_p\text{O}_2 S p ​ O 2 ​ of about 88-92% , because high inspired oxygen can worsen hypercapnia by releasing hypoxic pulmonary vasoconstriction (V/Q mismatch) and through the Haldane effect, rather than solely by loss of hypoxic drive.

Postoperative: regional analgesia, early mobilisation, physiotherapy, non-invasive ventilation for hypercapnic respiratory failure.

Obstructive Sleep Apnoea (OSA)

OSA is recurrent upper airway collapse during sleep. Severity is graded by the apnoea-hypopnoea index (AHI) : mild 5-14, moderate 15-29, severe 30 or more events per hour.

STOP-Bang Screening

  • Letter Criterion
  • S Snoring loudly
  • T Tiredness during the day
  • O Observed apnoeas
  • P Pressure: treated or untreated hypertension
  • B BMI above 35 kg/m²
  • A Age above 50 years
  • N Neck circumference above 40 cm
  • G Male gender

Score 0-2 low risk, 3-4 intermediate, 5-8 high risk.

Implications: difficult mask ventilation and intubation, sensitivity to opioids and sedatives, postoperative hypoxaemia (worst on nights 2-3 because of REM rebound). Patients should bring and use their CPAP device after surgery; use multimodal opioid-sparing analgesia, extubate fully awake in a semi-upright position, and monitor with continuous oximetry.

Obesity

Obesity is defined by body mass index (BMI): 30-34.9 class I, 35-39.9 class II, 40 or more class III (severe).

Physiological Changes

Respiratory: reduced functional residual capacity (especially supine and anaesthetised), atelectasis, rapid desaturation, increased work of breathing and oxygen consumption; obesity hypoventilation syndrome (BMI above 30 with daytime P a CO 2 P_a\text{CO}_2 P a ​ CO 2 ​ above 6 kPa) indicates high risk.

Cardiovascular: increased blood volume and cardiac output, hypertension, heart failure, atrial fibrillation, pulmonary hypertension.

Gastrointestinal: reflux and fatty liver disease; gastric volume is not reliably increased in fasted patients.

Venous thromboembolism risk is increased.

Weight Scalars for Drug Dosing

  • Drug Weight used Reason
  • Propofol (induction) Lean body weight Initial distribution to the central compartment
  • Propofol (maintenance infusion) Total or adjusted body weight Larger volume and clearance
  • Thiopental, fentanyl, remifentanil Lean body weight
  • Suxamethonium Total body weight Increased plasma cholinesterase and extracellular fluid
  • Rocuronium, vecuronium Ideal body weight Limited distribution into fat
  • Sugammadex Actual (total) body weight Per licence
  • Low molecular weight heparin (prophylaxis) Increased doses by weight band
  • Practical Management

Positioning: "ramped" with the external auditory meatus level with the sternal notch, head-up 25-30°, to improve laryngoscopy and FRC.

Preoxygenation with head-up position and CPAP or high-flow nasal oxygen prolongs safe apnoea time.

Ventilation: tidal volume 6-8 mL/kg predicted body weight, PEEP and recruitment manoeuvres.

Regional anaesthesia may be technically difficult; use ultrasound and longer needles.

Extubation fully awake, head-up, after full reversal confirmed with quantitative monitoring.

  • Liver Disease
  • Assessment of Severity
  • Child-Pugh variable 1 point 2 points 3 points
  • Bilirubin ( μ mol/L \mu\text{mol/L} μ mol/L ) Below 34 34-50 Above 50
  • Albumin (g/L) Above 35 28-35 Below 28
  • INR Below 1.7 1.7-2.3 Above 2.3
  • Ascites None Mild Moderate to severe
  • Encephalopathy None Grade 1-2 Grade 3-4

Class A 5-6 points, B 7-9, C 10-15. Reported perioperative mortality for abdominal surgery has been about 10% (A), 30% (B) and 75-80% (C) in older series. The MELD score (bilirubin, INR, creatinine, often with sodium) is also used.

Anaesthetic Implications

Hyperdynamic circulation with low systemic vascular resistance; portopulmonary hypertension and hepatopulmonary syndrome.

Coagulopathy and thrombocytopenia , though the haemostatic balance is "rebalanced"; viscoelastic testing guides correction better than the INR.

Drug handling: reduced albumin increases free fraction of acidic drugs; reduced hepatic clearance prolongs midazolam, morphine and aminosteroid relaxants; increased volume of distribution may raise initial requirements. Atracurium and cisatracurium (Hofmann degradation) and remifentanil (esterases) are useful.

Hepatic encephalopathy: avoid benzodiazepines; sedation may precipitate it.

Hepatorenal syndrome: functional renal failure from splanchnic vasodilation; avoid nephrotoxins and hypotension.

Maintain hepatic blood flow by avoiding hypotension; isoflurane and sevoflurane preserve hepatic arterial flow better than older agents.

Chronic Kidney Disease (CKD)

CKD is staged by estimated glomerular filtration rate (G1-G5; G5 below 15 mL/min/1.73 m²).

Systemic effects: hypertension, accelerated atherosclerosis, left ventricular hypertrophy, anaemia (reduced erythropoietin), uraemic platelet dysfunction, metabolic acidosis, hyperkalaemia, delayed gastric emptying and renal osteodystrophy.

Perioperative management:

Time surgery about 12-24 hours after dialysis, when volume and potassium are optimal; check potassium on the day.

Suxamethonium raises potassium by about 0.5 mmol/L and should be avoided if potassium is already high.

Prefer atracurium or cisatracurium ; rocuronium and vecuronium action is prolonged. Sugammadex-rocuronium complexes are not recommended in severe renal impairment (creatinine clearance below 30 mL/min) because their excretion is renal.

Opioids: avoid morphine (morphine-6-glucuronide and morphine-3-glucuronide accumulate) and pethidine (norpethidine causes seizures); fentanyl, alfentanil and remifentanil are safer.

Avoid NSAIDs and nephrotoxins in patients with residual function.

Protect arteriovenous fistulas: no cannulas or blood pressure cuffs on that arm; check the thrill after surgery.

Uraemic bleeding responds to desmopressin, dialysis and correction of anaemia.